Arena Pharmaceuticals, Inc. engages in discovering, developing and commercializing drugs to address unmet medical needs. Lorcaserin, the company’s approved drug, is approved for marketing in the United States and South Korea for the indication of weight management, and is being commercialized under the brand name BELVIQ (which is pronounced as BEL-VEEK). BELVIQ was made available by prescription in the United States in 2013 and in South Korea in 2015, and there are pending applications for the regulatory approval of BELVIQ for marketing in various additional territories. The company also has a pending application with the US Food and Drug Administration (FDA) for the regulatory approval of a once-daily formulation of BELVIQ, which is planned to be marketed under the brand name BELVIQ XR. The company has collaborations with pharmaceutical companies that provide them rights and responsibilities to seek regulatory approval and commercialize BELVIQ for weight management. These collaborations are with Eisai Inc. and Eisai Co., Ltd. (collectively, Eisai) for all of the countries in the world, except for South Korea, Taiwan, Israel, Australia and New Zealand; Ildong Pharmaceutical Co., Ltd. for South Korea; CY Biotech Company Limited for Taiwan; and Teva Pharmaceutical Industries Ltd.’s local Israeli subsidiary, Abic Marketing Limited for Israel. The company is developing a once-daily formulation of lorcaserin for potential use for weight management, which is planned to be marketed under the brand name BELVIQ XR. The company has collaborations with Eisai and other pharmaceutical companies for the marketing of BELVIQ in most of the world, and its Swiss subsidiary, Arena Pharmaceuticals GmbH (Arena GmbH), is responsible for manufacturing and supplying BELVIQ for these companies. In addition to BELVIQ, the company has a pipeline of drug candidates and other compounds at various stages of research and development, all of which have been internally discovered. Its drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases, and APD371 for pain. Its programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan G protein-coupled receptors (GPCR) for central nervous system (CNS), indication(s). The company has various earlier-stage programs. APD334, an orally available modulator of the S1P1 receptor, is the company’s internally discovered investigational drug candidate intended for the potential treatment of a number of autoimmune diseases, such as multiple sclerosis, psoriasis, inflammatory bowel diseases and rheumatoid arthritis. S1P1 receptors have been demonstrated to be involved in the modulation of various biological responses, including lymphocyte trafficking from lymph nodes to the peripheral blood. By isolating lymphocytes in lymph nodes, fewer immune cells are available in the circulating blood to effect tissue damage. In 2015, the company initiated patient dosing in a 12-week, randomized, double-blind and placebo-controlled Phase 2 clinical trial of APD334. Ralinepag, an orally available agonist of the IP receptor, is the company’s internally discovered investigational drug candidate intended for the treatment of pulmonary arterial hypertension (PAH). In 2015, the company initiated patient dosing in a 22-week, randomized, double-blind and placebo-controlled Phase 2 clinical trial of ralinepag. APD371, an orally available agonist of the CB2 receptor, is an internally discovered investigational drug candidate the company is exploring for the treatment of pain. In 2015, the company announced results from a Phase 1 single-ascending dose clinical trial of APD371. Nelotanserin Program Nelotanserin, an orally available inverse agonist of the serotonin 2A receptor, is an internally discovered investigational drug candidate that the company originally studied for sleep maintenance. Axovant Sciences Ltd. announced that it has initiated a Phase 2 clinical trial for nelotanserin in patients with dementia with Lewy Bodies, which includes Lewy Body and Parkinson’s disea
arena pharmaceuticals inc
6154 Nancy Ridge Drive
San Diego, CA 92121
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for ARNA.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact ARENA PHARMACEUTICALS INC, please visit www.arenapharm.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.